Size | Price | Stock | Qty |
---|---|---|---|
100mg |
|
||
500mg |
|
||
1g |
|
||
5g |
|
||
10g |
|
||
25g |
|
||
Other Sizes |
|
Purity: ≥98%
Baicalin is naturally occuring flavonoid glycoside found in several species in the genus Scutellaria, including Scutellaria lateriflora (blue skullcap). It is able to reduce the expression of NF-κB. There are 10 mg/g baicalin in Scutellaria galericulata (common skullcap) leaves. Baicalin is the glucuronide of baicalein. It is a component of Chinese medicinal herb Huang-chin (Scutellaria baicalensis) and one of the chemical ingredients of Sho-Saiko-To, an herbal supplement. Baicalin is a known prolyl endopeptidase inhibitor, induces apoptosis in pancreatic cancer cells, and affects the GABA receptors.
ln Vitro |
By modifying the synthesis of several mediators, including as reactive oxygen species (ROS), Toll-like receptors (TLR) 2 and TLR4, NF-κB, Bax, and Bcl-2, baicalin provides protection against reperfusion injury (IRI). The pro-inflammatory cytokines TLR2/4, MyD88, p-NF-κB, and p-IκB, as well as the enhanced production of NF-κB in correlation with IκB expression, are all inhibited by treatment [1]. The MTT assay was used to assess cell viability. When compared to control cells, the vitality of SH-SY5Y cells treated with powdered enzyme was much lower. When compared to cells treated with powdered enzyme alone, baicalin (5, 10, and 20 μM) alone enhanced cell viability in a dose-dependent way [2].
|
---|---|
ln Vivo |
For two quarters (10 and 100 mg/kg), baicalin dramatically decreased blood urea nitrogen (BUN) and Scr concentrations while also quantitatively preventing renal function loss. Using a 0–3 point grading system, the tissue damage caused by baicalin was evaluated. Treatment with 10 and 100 mg/kg baicalin resulted in only a minor increase in MDA content and a slight lowering of SOD activity when compared to the sham group, suggesting that baicalin increases oxidation when reinjection is removed [1].
|
References |
[1]. Lin M, et al. The protective effect of Baicalin against renal ischemia-reperfusion injury through inhibition of inflammation and apoptosis. BMC Complement Altern Med. 2014 Jan 13;14:19.
[2]. Ju XN, et al. Baicalin protects against thrombin induced cell injury in SH-SY5Y cells. Int J Clin Exp Pathol. 2015 Nov 1;8(11):14021-7. [3]. Dai J, et al. Chemoproteomics reveals baicalin activates hepatic CPT1 to ameliorate diet-induced obesity and hepatic steatosis. Proc Natl Acad Sci U S A. 2018;115(26):E5896-E5905 |
Molecular Formula |
C21H18O11
|
---|---|
Molecular Weight |
446.36
|
Exact Mass |
446.08491
|
CAS # |
21967-41-9
|
Related CAS # |
21967-41-9;
|
SMILES |
O=C([C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC2=CC3=C(C(O)=C2O)C(C=C(C4=CC=CC=C4)O3)=O)O1)O
|
Chemical Name |
(2S,3S,4S,5R,6S)-6-(5,6-dihydroxy-4-oxo-2-phenyl-chromen-7-yl)oxy-3,4,5-trihydroxy-tetrahydropyran-2-carboxylic acid
|
Synonyms |
Baicalin
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~224.03 mM)
H2O : < 0.1 mg/mL |
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.60 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.60 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: 20 mg/mL (44.81 mM) in 0.5% CMC-Na/saline water (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.2403 mL | 11.2017 mL | 22.4034 mL | |
5 mM | 0.4481 mL | 2.2403 mL | 4.4807 mL | |
10 mM | 0.2240 mL | 1.1202 mL | 2.2403 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.